

# Gastrointestinal Committee

## Leadership

Chair: ..... Philip A. Philip, MD, PhD, FRCP  
 Vice-Chair: ..... Elena G. Chiorean, MD  
 Executive Officer: ..... Christopher W. Ryan, MD  
 Statisticians: ..... Katherine A. Guthrie, PhD  
 ..... Sarah Colby, MS

## Scientific Leadership

Gastroesophageal: ..... Syma Iqbal, MD  
 ..... Zev A. Wainberg, MD  
 Pancreatic: ..... Davendra P.S. Sohal, MD  
 ..... Andrew M. Lowy, MD (Surgical representative)  
 Hepatobiliary: ..... Anthony B. El-Khoueiry, MD  
 ..... Rachna T. Shroff, MD  
 ..... Syed A. Ahmad, MD (Surgical representative)  
 Colon: ..... Marwan G. Fakhri, MD  
 ..... Philip J. Gold, MD  
 ..... Sepideh Gholami, MD (Surgical representative)  
 Neuroendocrine Tumors: ..... Nageshwara Arvind Dasari, MD  
 ..... Jonathan R. Strosberg, MD  
 Ano-Rectal: ..... Lisa A. Kachnic, MD  
 ..... Hagen F. Kennecke, MD  
 Imaging: ..... Anthony F. Shields, MD, PhD  
 Pathology: ..... Mary Kay Washington, MD, PhD  
 Radiation Oncology: ..... Lisa A. Kachnic, MD  
 Surgery: ..... Stephen W. Behrman, MD  
 ..... Syed A. Ahmad, MD  
 ..... Flavio Rocha, MD  
 Translational Medicine: ..... Gabriel N. Duda, PhD, DMD  
 ..... Maheswari Senthil, MD

## Designates

Cancer Control Liaisons: ..... Jason A. Zell, DO (Prevention)  
 ..... Afsaneh Barzi, MD (CCD)  
 Community Liaisons: Gary L. Buchsacher, MD, PhD (Medical Oncology)  
 ..... Mohamed E. Salem, MD (Medical Oncology)  
 ..... Flavio Rocha, MD (Surgical)  
 ..... David Horowitz, MD (Radiation Oncology)  
 ..... Mark A. O'Rourke, MD (Palliative Care)  
 DEI Champion: ..... Colmar Figueroa-Moseley, PhD, MPH  
 ..... Rachael Ann Safyan, MD  
 Digital Engagement: ..... Heloisa Soares, MD, PhD  
 Data Coordinators: ..... Alex Rangel, BS  
 ..... Brian Zeller  
 ..... Christine Magner  
 Oncology Research Professionals:  
 CRA: ..... Michelle A. Springer, BA  
 Nurse: ..... TBD

Patient Advocate (Pancreatic): ..... Carole Seigel, MBA  
 Patient Advocate (Colon): ..... Florence Kurttila, MS  
 Pharmaceutical Science: ..... Jane E. Rogers, PharmD  
 ..... Safae Chouraichi, PharmD  
 Protocol Project Manager: ..... Andrea Garcia  
 Clinical Trials Program Manager: ..... Laura Gildner, MS

## Time/Location

Friday, October 13, 2023 4:30 p.m. - 6:30 p.m.  
 Room: Regency D (Ballroom Level, West Tower)

## Agenda

1. Welcome
2. Announcements & Introductions
 

Philip Philip	
E. Gabriella Chiorean	
3. DEI Subcommittee Initiatives
 

Rachel Safyan, Colmar	
Figueroa-Moseley, Carole Seigel, Florence Kurttila	
4. SWOG GI Committee Led Trials
 

a.	S1922	Michael Overman
b.	S2001	Vincent Chung
c.	S2104	Heloisa Soares/Syed Ahmad
d.	S2107	Van Morris
e.	S0802	Jason Zell
f.	S2012	David Zhen
g.	S2303	Anwaar Saeed/Paul Oberstein
5. Correlative Science Updates
 

a.	S1505	Davendra Sohal/Andy Lowy
----	-------	--------------------------
6. Anal and Rectal
 

Hagen Kennecke, Lisa Kachnic	
------------------------------	--

  - a. Major recent clinical results
  - b. NCTN trials update
  - c. Future SWOG plans
7. Colon
 

Marwan Fakhri, Philip Gold,	
Sepideh Gholami	

  - a. Major recent clinical results
  - b. NCTN trials update
  - c. Future SWOG plans
8. Gastroesophageal
 

Syma Iqbal, Zev Wainberg	
--------------------------	--

  - a. Major recent clinical results
  - b. NCTN trials update
  - c. Future SWOG plans

# Gastrointestinal Committee

## 9. Hepatobiliary

Anthony El-Khoueiry,  
Rachna Shroff

FOLFIRINOX in Resectable and Borderline Resectable Pancreatic Adenocarcinoma" Dr. Sohal, Dr. Pillarisetty

- a. Major recent clinical results
- b. NCTN trials update
- c. Future SWOG plans

### Active Studies

**S2001**, "Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations." Dr. Chung. Activated: 12/4/20.

**CTSU/A021804**, "A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma." Dr. C. Lopez. Activated: 11/2/20.

**CTSU/A021806**, "A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer." Dr. Noel. Activated: 7/1/20.

**CTSU/EA2186**, "A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT)." Dr. Zhen. Activated: 6/18/20.

**CTSU/EA2192**, "APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation." Drs. Chiorean and Philip. Activated: 4/29/21.

## 10. Neuroendocrine

Jon Strosberg, Arvind Dasari

- a. Major recent clinical results
- b. NCTN trials update
- c. Future SWOG plans

## Neuroendocrine

### Active Studies

**S2104**, "Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors." Dr. Soares. Activated: 10/14/21.

**S2012**, "Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas." Activated Drs. D. Zhen, E. Chiorean, E. Burgess, E. Swisher, L. Byers. Activated: 12/02/2021

**CTSU/A021602**, "Randomized Double-Blinded Phase III Study of CABozantinib versus Placebo IN Advanced Neuroendocrine Tumors after Progression on Prior Therapy (CABINET)." Dr. Strosberg. Activated: 7/18/18. Temporarily Closed to Accrual as of 08/07/2023

## 11. Pancreatic

Davendra Sohal, Andrew Lowy

- a. Major recent clinical results
- b. NCTN trials update
- c. Future SWOG plans

## Hepatobiliary

### Active Studies

## 12. Discussion/Other Business

## 13. Adjourn

## Gastroesophageal

### Developing Studies

**S2303**, "Phase II/III Trial of Nivolumab + Cabozantinib or Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS  $\geq$  5 Advanced Gastric and Esophageal Adenocarcinoma." Dr. Saeed.

### Active Studies

**CTSU/A022102**, "Randomized Phase III Trial of mFOLFIRINOX +/- Nivolumab vs. FOLFOX +/- Nivolumab for First-Line Treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma." Dr. Oberstein. Activated: 1/17/19.

**CTSU/EA2174**, "A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma." Dr. Kelly. Activated: 1/17/19. Temporarily Closed to Accrual as of 12/29/2022.

**CTSU/EA2183**, "A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)." Dr. Horowitz. Activated: 2/6/2020.

## Pancreatic

### Developing Studies

**S2411**, "A Randomized Phase II Study of Neoadjuvant Nadunolimab + FOLFIRINOX vs Cemiplimab + Motixafortide + FOLFIRINOX vs

# Gastrointestinal Committee

**CTSU/NRG-GI003**, "A Phase III Randomized Trial of Protons Versus Photons for Hepatocellular Carcinoma." Dr. El-Khoueiry. Activated: 6/21/17.

**CTSU/EA2197**, "Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial." Dr. Rocha. Activated: 12/22/20.

## Closed Studies

**S1815**, "A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers." Dr. Shroff. Activated: 12/3/18. Permanently Closed: 2/15/21.

**CTSU/EA2187**, "A Phase 2 Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma." Dr. Stein. Activated: 1/31/20. Permanently Closed: 03/22/2023.

## Colorectal

### Active Studies

**A022101**, "A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)" SWOG Champion: S. Gholami Activated: 1/10/23.

**S2107**, "Randomized Phase II Trial of Encorafenib and Cetuximab with or without Nivolumab for Patients with Microsatellite Stable, BRAFV600E Metastatic Colorectal Cancer." Dr. Morris. Activated: 6/06/22.

**CTSU/NRG-GI008**, Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US) SWOG GI Committee Co-Chairs: P. Philip & C. Eng Activated: 03/10/2022

**CTSU/NRG-GI005**, "Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)." Dr. Scott. Activated: 12/16/19.

**CTSU/NRG-GI004/ S1610**, "Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination versus Single Agent Atezolizumab in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer." Dr. Overman. Activated: 11/7/17.

### Closed Studies

**S1613**, "A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP

Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification." Dr. Raghav. Activated: 10/19/17. Step 1 closed to accrual: 1/1/2022.

**S0820**, "A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III – Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)." Dr. Zell. Activated: 3/1/13. Permanently Closed: 6/30/2023

**CTSU/A021502**, "Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair." Dr. Lieu. Activated: 9/12/17. Permanently Closed: 01/17/2023

**CTSU/A021703**, "Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)." Dr. Cohen. Activated: 9/30/19. Permanently Closed: 12/15/2022.

## Anal

### Active Studies

**A022104**, "The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing the Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients with Locally Advanced Rectal Cancer" Activated 11/9/2022. SWOG Champion: A. Dasari

**CTSU/EA2176**, "Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer Patients." Dr. Morris. Activated: 10/15/20.

**CTSU/EA2182**, "A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)." Dr. Murphy. Activated: 11/12/19.

**CTSU/EA2201**, "A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma." Dr. Cho. Activated 5/13/21.

## Other

### Developing Studies

**S2408**, "A Randomized Phase III Multicenter Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula" Dr. Sham, Submitted to DCP 7/28/2023.

## Gastrointestinal Committee

### Accrual from trial opening through 6/30/2023 by Institution and Study

	S1613	S1922	S2001	S2104	S2107	A021502	A021602	A021703	A021806
Ascension Providence Hospitals - Southfield	-	-	2	-	-	3	-	-	-
Banner University Medical Center - Tucson	-	-	-	3	-	2	3	-	1
Baptist Memorial Health Care/Mid South Minority Underserved	-	-	2	-	-	-	-	-	-
Baylor College of Medicine/Duncan Comprehensive Cancer Center	-	-	-	-	-	-	-	1	-
Boston Medical Center	-	-	-	-	-	1	3	-	1
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	6	-	-	2
Cancer Research Consortium of West Michigan NCORP	-	-	-	-	2	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	1	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	2	-	-	-	1	-	-
Columbia University Minority Underserved NCORP	-	-	1	-	-	-	-	-	-
CommonSpirit Health Research Institute	3	-	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	-	3	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	-	4	-	-	1
Hawaii Minority Underserved NCORP	1	-	-	-	-	-	-	-	-
Heartland Cancer Research NCORP	3	-	-	-	3	-	-	-	-
Henry Ford Hospital	-	-	1	-	-	-	-	-	-
Houston Methodist Hospital	-	-	-	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	2	-	-	-	3	17	-	-	-
Lahey Hospital and Medical Center	1	-	-	-	-	-	-	-	-
Loyola University Medical Center	1	-	-	-	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	-	-	1	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	1	1	2	-	-	-	-	-	-
Moffitt Cancer Center	-	-	-	-	-	-	4	-	-
Montana Cancer Consortium NCORP	-	-	-	-	1	-	-	-	-
Northwell Health NCORP	-	-	-	-	-	-	-	9	1
Northwestern University LAPS	1	1	-	-	-	1	-	8	-
Oregon Health and Science University	-	-	-	-	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	3	-	-	1	2	-	-	-	-
STCC at DHR Health Institute for Research and Development	-	-	-	-	-	-	-	-	-

## Gastrointestinal Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	S1613	S1922	S2001	S2104	S2107	A021502	A021602	A021703	A021806
Southeast Clinical Oncology Research Consortium NCORP	1	-	2	2	2	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	-	-	3	-	-	-
The Don and Sybil Harrington Cancer Center	-	-	-	-	-	-	-	-	2
The West Clinic - Wolf River	-	-	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	2	-	-	-	-	4	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	2	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	1	-	-	-	-	2	-	1	-
University of Arkansas for Medical Sciences	-	-	-	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	-	-	-	3	-
University of Colorado Cancer Center LAPS	1	-	2	-	-	6	-	1	-
University of Kansas Cancer Center - MCA Rural MU NCORP	4	-	-	-	-	3	-	1	-
University of Kentucky/Markey Cancer Center	-	-	-	3	-	-	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	1	3	2	1	-	-	2	-	4
University of Rochester LAPS	-	1	-	-	-	2	8	-	6
University of Texas Health Science Center at San Antonio	-	-	-	-	-	-	-	-	3
University of Texas MD Anderson Cancer Center LAPS	13	9	-	-	4	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	1	2	-	-	-	-	-
University of Wisconsin Carbone Cancer Center	-	-	-	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	3	-	-	-	-	-	-
Virginia Mason Medical Center	-	-	-	-	-	4	2	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	1	-	-	2	-	-	-
William Beaumont Hospital-Royal Oak	-	-	-	-	-	1	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-	1	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	-	4	-	8	1
ALLIANCE	6	9	5	-	4	-	-	-	-
ECOG-ACRIN	4	1	6	2	2	-	-	-	-
NRG	5	2	3	4	4	-	-	-	-
<b>Total</b>	<b>54</b>	<b>28</b>	<b>37</b>	<b>19</b>	<b>28</b>	<b>68</b>	<b>23</b>	<b>32</b>	<b>22</b>

## Gastrointestinal Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	A022102	A022104	EA2174	EA2176	EA2182	EA2186	EA2187	EA2192	EA2197	NRGGI004
Ascension Providence Hospitals - Southfield	-	-	-	1	2	2	-	-	-	-
Banner University Medical Center - Tucson	-	-	-	-	-	-	-	-	-	-
Baptist Mem Hlth Care/Mid South MU-NCORP	-	-	-	-	-	-	-	-	-	-
Baylor College of Med/Dan L Duncan CCC	-	-	-	-	-	-	-	-	-	-
Boston Medical Center	2	-	2	-	2	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	2	-	2	1	3	-	-	-
Cancer Research Consortium of West Michigan	-	-	-	-	-	-	-	-	-	-
Carle Cancer Center NCI Comm Oncology Research Program	-	-	-	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-	-	2	-	-	-	-
Columbia University Minority Underserved NCORP	-	-	-	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	-	1	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	-	1	-	-	-	-
Hawaii Minority Underserved NCORP	-	-	-	-	-	2	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-	-	-	-	-	-	-
Henry Ford Hospital	-	-	-	-	-	-	-	-	-	-
Houston Methodist Hospital	-	-	-	-	-	-	-	-	-	1
Kaiser Permanente NCORP	-	-	-	4	-	-	-	-	-	-
Lahey Hospital and Medical Center	-	-	-	-	-	-	-	-	-	-
Loyola University Medical Center	-	-	-	-	-	-	-	-	-	-
Medical U of South Carolina Minority Underserved	-	-	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-	-	-	-	-	-	-
Moffitt Cancer Center	-	-	-	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-	-	-	-	-
Northwell Health NCORP	-	-	1	-	-	2	-	-	-	-
Northwestern University LAPS	-	-	-	1	-	1	-	-	-	-
Oregon Health and Science University	-	-	-	2	1	-	-	1	3	-
Pacific Cancer Research Consortium NCORP	-	-	-	-	-	-	-	-	-	-
STCC at DHR Hlth Inst for Res & Dev	-	-	-	-	-	-	-	-	-	-

## Gastrointestinal Committee

### Accrual from trial opening through 6/30/2023 by Institution and Study

	A022102	A022104	EA2174	EA2176	EA2182	EA2186	EA2187	EA2192	EA2197	NRGGI004
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	-	-	-	1	-	-	-
The Don and Sybil Harrington Cancer Center	-	-	-	-	-	-	-	-	-	-
The West Clinic - Wolf River	-	2	-	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	1	-	-	-	-	-	-	1	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-	2	-	2	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	1	-	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	-	1	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	1	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	-	-	-	-	-	1	-	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-	-	-	-	1	-	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-	-	-	-	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-
University of Rochester LAPS	-	-	-	-	-	5	2	-	-	1
University of Texas Health Science Center at San Antonio	-	-	-	-	-	3	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-	7	-	-	-	-	-	12
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	-	-	-	-	-	-
University of Wisconsin Carbone Cancer Center	-	-	-	-	-	-	-	-	-	1
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-
Virginia Mason Medical Center	-	-	-	-	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-	1	-	-	-	-	-
William Beaumont Hospital-Royal Oak	-	-	-	-	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-	-	-	-
<b>Total</b>	<b>2</b>	<b>3</b>	<b>6</b>	<b>19</b>	<b>8</b>	<b>23</b>	<b>7</b>	<b>1</b>	<b>4</b>	<b>15</b>



## Gastrointestinal Committee

### Accrual from trial opening through 6/30/2023 by Institution and Study

	NRGGI005	NRGGI008		NRGGI005	NRGGI008
Ascension Providence Hospitals - Southfield	5	1	Southeast Clinical Oncology Research Consortium	-	-
Banner University Medical Center - Tucson	-	-	Sutter Cancer Research Consortium	-	-
Baptist Mem Hlth Care/Mid South MU-NCORP	3	1	The Don and Sybil Harrington Cancer Center	-	-
Baylor College of Med/Dan L Duncan CCC	-	-	The West Clinic - Wolf River	-	1
Boston Medical Center	-	-	UC Davis Comprehensive Cancer Center LAPS	1	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	UC Irvine Health/Chao Family Comprehensive Cancer Cntr	1	-
Cancer Research Consortium of West Michigan	-	-	USC Norris Comprehensive Cancer Center LAPS	-	-
Carle Cancer Cntr NCI Comm Oncology Research Program	-	-	University of Arkansas for Medical Sciences	-	-
City of Hope Comprehensive Cancer Center	-	-	University of Cincinnati Cancer Center-UC Medical Center	-	-
Columbia University Minority Underserved NCORP	-	-	University of Colorado Cancer Center LAPS	-	1
CommonSpirit Health Research Institute	-	-	University of Kansas Cancer Center - MCA Rural MU NCORP	2	-
Dayton NCI Community Oncology Research Program	1	-	University of Kentucky/Markey Cancer Center	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	University of Michigan Comprehensive Cancer Center LAPS	-	-
Hawaii Minority Underserved NCORP	-	-	University of Rochester LAPS	-	-
Heartland Cancer Research NCORP	-	-	University of Texas Health Science Center at San Antonio	-	-
Henry Ford Hospital	1	-	University of Texas MD Anderson Cancer Center LAPS	1	-
Houston Methodist Hospital	-	-	University of Utah - Huntsman Cancer Institute LAPS	-	-
Kaiser Permanente NCORP	11	-	University of Wisconsin Carbone Cancer Center	-	-
Lahey Hospital and Medical Center	-	-	Vanderbilt University - Ingram Cancer Center LAPS	1	1
Loyola University Medical Center	-	-	Virginia Mason Medical Center	-	-
Medical U of South Carolina Minority Underserved	-	-	Wayne State University - Karmanos Cancer Institute LAPS	-	-
Michigan Cancer Research Consortium NCORP	1	-	William Beaumont Hospital-Royal Oak	-	-
Moffitt Cancer Center	-	-	Wisconsin NCI Community Oncology Research Program	-	-
Montana Cancer Consortium NCORP	-	-	Yale University - Yale Cancer Center LAPS	4	-
Northwell Health NCORP	1	1	ALLIANCE	-	-
Northwestern University LAPS	-	-	ECOG-ACRIN	-	-
Oregon Health and Science University	1	-	NRG	-	-
Pacific Cancer Research Consortium NCORP	-	-	<b>Total</b>	<b>35</b>	<b>6</b>
STCC at DHR Hlth Inst for Res & Dev	1	-			